Baxter Hlthcare Company Profile

What is the competitive landscape for BAXTER HLTHCARE, and when can generic versions of BAXTER HLTHCARE drugs launch?

BAXTER HLTHCARE has two hundred and five approved drugs.

There are fifteen US patents protecting BAXTER HLTHCARE drugs. There are three tentative approvals on BAXTER HLTHCARE drugs.

There are forty-nine patent family members on BAXTER HLTHCARE drugs in twenty countries and two hundred and sixty-seven supplementary protection certificates in fifteen countries.

Summary for Baxter Hlthcare

International Patents:	49
US Patents:	15
Tradenames:	318
Ingredients:	119
NDAs:	205

Drugs and US Patents for Baxter Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	020734-018	Sep 29, 1997		RX	No	No
Baxter Hlthcare Corp	BUTORPHANOL TARTRATE PRESERVATIVE FREE	butorphanol tartrate	INJECTABLE;INJECTION	075695-001	Oct 23, 2001		DISCN	No	No
Baxter Hlthcare	PLASMA-LYTE A IN PLASTIC CONTAINER	magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium gluconate	INJECTABLE;INJECTION	017378-002	Nov 22, 1982		RX	Yes	Yes
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No	10,583,155		Y

Expired US Patents for Baxter Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	BREVIBLOC	esmolol hydrochloride	INJECTABLE;INJECTION	019386-007	May 28, 2003	4,593,119*PED
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718-002	Jun 13, 2000	5,213,804
Baxter Hlthcare	CYTOXAN (LYOPHILIZED)	cyclophosphamide	INJECTABLE;INJECTION	012142-009	Dec 10, 1985	4,537,883
Baxter Hlthcare	LYOPHILIZED CYTOXAN	cyclophosphamide	INJECTABLE;INJECTION	012142-007	Dec 10, 1985	4,537,883

Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Inhalation	99.90%		2008-09-11
	Injection	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags		2014-01-31

International Patents for Baxter Hlthcare Drugs

Country	Patent Number	Estimated Expiration
Hong Kong	1219883
European Patent Office	2402008
Japan	2017019879
European Patent Office	1501496

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0489070	300162	Netherlands		PRODUCT NAME: BIVALIRUDINE; FIRST REGISTRATION,DATE: EU/1/04/289/001, 20040920
2673237	LUC00111	Luxembourg		PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326
0306228	SPC/GB01/002	United Kingdom		PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
1224170	SPC/GB15/018	United Kingdom		PRODUCT NAME: NINTEDANIB*, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE. *NINTEDANIB IS 3-Z-(1-(4-N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-METHYL-AMINO)-A; REGISTERED: UK EU/1/14/954/001 20141125; UK EU/1/14/954/002 20141125; UK EU/1/14/954/003 20141125; UK EU/1/14/954/004 20141125

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Baxter Hlthcare
• Baxter Hlthcare Corp